Qigong Exercise May Benefit Patients With Fibromyalgia

Fibromyalgia Clinical Trial

Official title:

Qigong Exercise May Benefit Patients With Fibromyalgia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01333566
• Other study ID #: 11889
• Status: Completed
• Phase: N/A
• First received: April 8, 2011
• Last updated: July 1, 2016
• Start date: July 2009
• Est. completion date: February 2015

Study information

• Verified date: July 2016
• Source: University of Kansas Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The long-term goal of our research program is to develop an effective and cost-saving mind-body therapy to help patients with FM. The objective of this pilot study is to gather pilot data of the effect on pain, fatigue, sleep quality, and quality of life in FM patients using a specific type of qigong exercise, i.e. "six healing sound" qigong. Changes in relevant brain activity will be monitored in study subjects before and after the qigong exercise program, which may help us in better understanding the underlying mechanism of the qigong exercise. Data collected in this pilot study will help the investigators in preparation for a future clinical trial with a larger sample size. Our central hypothesis for the future clinical trial is that qigong exercise will lead to a significantly greater improvement in pain, fatigue, sleep quality, and quality of life in the experimental group compared to the control group.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: February 2015
• Est. primary completion date: February 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients with a diagnosis of primary FM, based on the 1990 American College of Rheumatology criteria (Wolfe et al, 1990),

• between the ages of 18 and 70 years;

• willing to withdraw from CNS-active therapies commonly used to treat FM; willing to discontinue treatment with transcutaneous electrical nerve stimulation, biofeedback, tender- and trigger-point injections, acupuncture, and anesthetic or narcotic patches;

• with a raw score > 4 on the physical function component of the Fibromyalgia Impact Questionnaire (FIQ) (Burckhardt et al, 1991);

• and a mean visual analog scale (VAS) pain score > 40 on a scale from 0 to 100.

Exclusion Criteria:

• severe psychiatric illness;

• a current major depressive episode (as determined by a Beck Depression Inventory (Beck et al, 1961) score >25);

• significant suicide risk;

• abuse of alcohol, benzodiazepines, or other drugs; a history of behavior that would prohibit compliance for the duration of the study;

• active cardiovascular, pulmonary, hepatic, renal, gastrointestinal, or autoimmune disease (except Hashimoto's or Graves' disease that had been stable for 3 months before screening);

• current systemic infection; active cancer (except basal cell carcinoma); unstable endocrine disease; severe sleep apnea;

• prostate enlargement or other genitourinary disorder (male patients);

• or pregnancy or breastfeeding (female patients).

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Fibromyalgia
• Myofascial Pain Syndromes

Intervention

Behavioral:
• Intervention Group
The study will include one week baseline phase, 6-week intervention phase, and a 3-month follow-up evaluation. Subjects in the intervention group will go through three training sessions during the baseline phase, weekly group exercise sessions once per week and daily home exercises two times each day during the intervention phase, and a follow-up evaluation in three months after the intervention phase.
• Placebo Comparator: Control Group
Subjects in the control group will be monitored during the baseline and intervention phase without participating in the interventional exercise. At the end of intervention phase, the subjects will have the option to stop their participation or switch to the intervention group.

Locations

Country	Name	City	State
United States	University Of Kansas Medical Center	Kansas City	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
University of Kansas Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To investigate the effect of qigong exercise on pain		up to 3months	No
Secondary	To investigate the effect of qigong exercise on fatigue		up to 3 months	No
Secondary	To investigate the effect of qigong exercise on sleep quality		up to 3 months	No
Secondary	To investigate the effect of qigong exercise the quality of life in FM patients.		up to 3 months	No